Co-Diagnostics (CODX) Q3 2025 Earnings Transcript

Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

Co-Diagnostics Reports Third Quarter 2025 Financial Results

Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with ...